Abstract
OBJECTIVES: Breath composition may be suggestive of different conditions. E-nose technology has been used to profile volatile organic compounds (VOCs) pattern in the breath of patients compared with that of healthy individuals. BIOsensor-based multisensorial system for mimicking NOse, Tongue and Eyes (BIONOTE) technology differs from Cyranose® based on a set of separate transduction features. On the basis of our previously published experience, we investigated the discriminating ability of BIONOTE in a high-risk population enrolled in a lung cancer screening programme. METHODS: One hundred individuals were selected for BIONOTE based on the attribution to the high-risk category (i.e. age, smoking status, chronic obstructive pulmonary disease status) of the University Campus Bio-Medico lung screening programme. We used a measure chain consisting of (i) a device named Pneumopipe (EU patent: EP2641537 (A1):2013-09-25) able to catch exhaled breath by an individual normally breathing into it and collect the exhalate onto an adsorbing cartridge; (ii) an apparatus for thermal desorption of the cartridge into the sensors chamber and (iii) a gas sensor array which is part of a sensorial platform named BIONOTE for the VOCs mixture analysis. Partial least square (PLS) has been used to build up the model, with Leave-One-Out cross-validation criterion. Each breath fingerprint analysis costs €10. RESULTS: The overall sensitivity and specificity were 86 and 95%, respectively, delineating a substantial difference between patients and healthy individuals. CONCLUSIONS: Our preliminary data show that BIONOTE technology may be used to reduce false-positive rates resulting from lung cancer screening with low-dose computed tomography in a cost-effective fashion. The model will be tested on a larger number of patients to confirm the reliability of these results.
| Original language | English |
|---|---|
| Article number | ezv328 |
| Pages (from-to) | 1112-1117 |
| Number of pages | 6 |
| Journal | European Journal of Cardio-thoracic Surgery |
| Volume | 49 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 1 2016 |
Fingerprint
Keywords
- E-nose
- Lung cancer
- Screening
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Surgery
- Pulmonary and Respiratory Medicine
Cite this
BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes. / Rocco, Raffaele; Incalzi, Raffaele Antonelli; Pennazza, Giorgio; Santonico, Marco; Pedone, Claudio; Bartoli, Isaura Rossi; Vernile, Chiara; Mangiameli, Giuseppe; Rocca, Antonello La; De Luca, Giuseppe; Rocco, Gaetano; Crucitti, Pierfilippo.
In: European Journal of Cardio-thoracic Surgery, Vol. 49, No. 4, ezv328, 01.04.2016, p. 1112-1117.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes
AU - Rocco, Raffaele
AU - Incalzi, Raffaele Antonelli
AU - Pennazza, Giorgio
AU - Santonico, Marco
AU - Pedone, Claudio
AU - Bartoli, Isaura Rossi
AU - Vernile, Chiara
AU - Mangiameli, Giuseppe
AU - Rocca, Antonello La
AU - De Luca, Giuseppe
AU - Rocco, Gaetano
AU - Crucitti, Pierfilippo
PY - 2016/4/1
Y1 - 2016/4/1
N2 - OBJECTIVES: Breath composition may be suggestive of different conditions. E-nose technology has been used to profile volatile organic compounds (VOCs) pattern in the breath of patients compared with that of healthy individuals. BIOsensor-based multisensorial system for mimicking NOse, Tongue and Eyes (BIONOTE) technology differs from Cyranose® based on a set of separate transduction features. On the basis of our previously published experience, we investigated the discriminating ability of BIONOTE in a high-risk population enrolled in a lung cancer screening programme. METHODS: One hundred individuals were selected for BIONOTE based on the attribution to the high-risk category (i.e. age, smoking status, chronic obstructive pulmonary disease status) of the University Campus Bio-Medico lung screening programme. We used a measure chain consisting of (i) a device named Pneumopipe (EU patent: EP2641537 (A1):2013-09-25) able to catch exhaled breath by an individual normally breathing into it and collect the exhalate onto an adsorbing cartridge; (ii) an apparatus for thermal desorption of the cartridge into the sensors chamber and (iii) a gas sensor array which is part of a sensorial platform named BIONOTE for the VOCs mixture analysis. Partial least square (PLS) has been used to build up the model, with Leave-One-Out cross-validation criterion. Each breath fingerprint analysis costs €10. RESULTS: The overall sensitivity and specificity were 86 and 95%, respectively, delineating a substantial difference between patients and healthy individuals. CONCLUSIONS: Our preliminary data show that BIONOTE technology may be used to reduce false-positive rates resulting from lung cancer screening with low-dose computed tomography in a cost-effective fashion. The model will be tested on a larger number of patients to confirm the reliability of these results.
AB - OBJECTIVES: Breath composition may be suggestive of different conditions. E-nose technology has been used to profile volatile organic compounds (VOCs) pattern in the breath of patients compared with that of healthy individuals. BIOsensor-based multisensorial system for mimicking NOse, Tongue and Eyes (BIONOTE) technology differs from Cyranose® based on a set of separate transduction features. On the basis of our previously published experience, we investigated the discriminating ability of BIONOTE in a high-risk population enrolled in a lung cancer screening programme. METHODS: One hundred individuals were selected for BIONOTE based on the attribution to the high-risk category (i.e. age, smoking status, chronic obstructive pulmonary disease status) of the University Campus Bio-Medico lung screening programme. We used a measure chain consisting of (i) a device named Pneumopipe (EU patent: EP2641537 (A1):2013-09-25) able to catch exhaled breath by an individual normally breathing into it and collect the exhalate onto an adsorbing cartridge; (ii) an apparatus for thermal desorption of the cartridge into the sensors chamber and (iii) a gas sensor array which is part of a sensorial platform named BIONOTE for the VOCs mixture analysis. Partial least square (PLS) has been used to build up the model, with Leave-One-Out cross-validation criterion. Each breath fingerprint analysis costs €10. RESULTS: The overall sensitivity and specificity were 86 and 95%, respectively, delineating a substantial difference between patients and healthy individuals. CONCLUSIONS: Our preliminary data show that BIONOTE technology may be used to reduce false-positive rates resulting from lung cancer screening with low-dose computed tomography in a cost-effective fashion. The model will be tested on a larger number of patients to confirm the reliability of these results.
KW - E-nose
KW - Lung cancer
KW - Screening
UR - http://www.scopus.com/inward/record.url?scp=84963772879&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963772879&partnerID=8YFLogxK
U2 - 10.1093/ejcts/ezv328
DO - 10.1093/ejcts/ezv328
M3 - Article
VL - 49
SP - 1112
EP - 1117
JO - European Journal of Cardio-thoracic Surgery
JF - European Journal of Cardio-thoracic Surgery
SN - 1010-7940
IS - 4
M1 - ezv328
ER -